Cytologic diagnosis of malignant mesothelioma in serous effusions using an antimesothelial-cell antibody.
Differentiating mesothelioma, reactive mesothelium, and adenocarcinoma in serous effusions is often difficult, despite the application of ancillary techniques in support of the traditional cytomorphologic criteria. A polyclonal antimesothelial-cell antibody recently developed by our group was evaluated as a histogenetic marker on a series of primary (n = 12) and metastatic (n = 12) malignant effusions. Immunostaining was performed on paraffin sections from cell blocks. All mesothelioma effusions stained positive for the antibody, whereas, in contrast, all metastatic carcinoma specimens failed to react. These results (100 percent specificity and 100% sensitivity for mesothelioma) provide a basis for a reliable use of the antibody in the cytologic examination of suspicious or malignant serous effusions.
Donna
A
A
Department of Pathology, City Hospital, Alessandria, Italy.
Betta
P G
PG
Bellingeri
D
D
Tallarida
F
F
Pavesi
M
M
Pastormerlo
M
M
D000230:Adenocarcinoma / Q000276:immunology / Q000473:pathology*; D001202:Ascitic Fluid / Q000473:pathology*; D015415:Biomarkers; D006801:Humans; D007124:Immunoenzyme Techniques; D008654:Mesothelioma / Q000276:immunology / Q000473:pathology*; D010996:Pleural Effusion / Q000473:pathology*
D015415:Biomarkers